Article
Epigallocatechin-3-gallate Alleviates Cognitive Deficits in APP/PS1 Mice.
Current medical science - 1 Feb 2020
Bao Jian, Liu Wei, Zhou Hong-Yan, Gui Yu-Ran, Yang You-Hua, Wu Meng-Juan, Xiao Yi-Fan, Shang Jin-Ting, Long Gui-Feng, Shu Xi-Ji
Abstract excerpt
Alzheimer's disease (AD) shows cognitive impairments in clinic, which is multifactorial with different etiopathogenic mechanisms such as Aβ deposition, neuroinflammation and neuronal dystrophy involved. Therefore, multi-targets drugs with neuroprotective, anti-amyloidogenic and anti-inflammatory properties will be effective in AD treatment. Epigallocatechin-3-gallate (EGCG) possesses a broad spectrum of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
